Your search for esrd returned 64 results

Canagliflozin decreases the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes, according to a new study.

Patients with end-stage kidney disease (ESKD) undergoing maintenance dialysis express a desire to exercise to regain energy and strength, but many report barriers to exercise.

The researchers found that an estimated 1% absolute increase in quarterly ILI correlated with a 1.5% increase and a 2.0% increase in relative mortality for quarters 4 and 1, respectively.

“We believe that the data actually suggest possible benefit for ESKD [end-stage kidney disease] with intensive glucose control, and remain inconclusive for intensive blood pressure control and fibrate use given the wide confidence intervals for the more reliable ESKD outcomes,” write the authors.

“CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children,” the authors write.

Compared to the placebo group, the LPP group had reduced reactivity to a conjunctival provocation test (P<0.001) and, during the pollen season, a lower rhinoconjunctivitis quality of life global score (P=0.005).

Shorter sleep duration, greater sleep fragmentation linked to greater decline in eGFR

Dialyzed patients have higher in-hospital mortality, hemorrhagic complications after RFA for HCC

Total of 26.6 and 27 percent of patients experienced anxiety, depression with initiation of RRT

Increased SBP variability tied to mortality, coronary heart disease, stroke, end-stage renal disease